Genetically modified mesenchymal stem cell that express an exogenous cytotoxic protein
AssigneeApceth GmbH & Co. KG
InventorPeter Nelson
Life of this patent
Estimating the term…
Abstract
This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method.
Claims30
A method for treating a subject afflicted with a tumor comprising introducing into the subject's bloodstream a therapeutically effective number of genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a RANTES promoter.
A genetically modified mesenchymal stem cell comprising an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a RANTES promoter.
An isolated genetically modified human CD34− stem cell comprising an exogenous nucleic acid comprising (i) a Herpes simplex viral thymidine kinase-encoding region operably linked to (ii) a RANTES promoter.
Dependencies are inferred from the claim text.